XLO (STOCKS)
Xilio Therapeutics, Inc. Common Stock
$8.460000
-0.050000 (-0.59%)
Prev close: $8.510000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- René Russo
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $49.50M
- Employees
- 73
- P/E (TTM)
- -1.52
- P/B (TTM)
- 1.09
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
2
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.81 | $-1.70 | +2.5068 | +147.74% |
|
Sep 2025 (Q3)
|
$-0.08 | $-0.42 | +0.3402 | +80.20% |
|
Jun 2025 (Q2)
|
$-2.24 | $-1.13 | -1.1088 | -98.02% |
|
Mar 2025 (Q1)
|
$-2.52 | $1.34 | -3.8633 | -287.60% |
Financial Statements
| Revenues | $43.77M |
| Benefits Costs and Expenses | $78.80M |
| Costs And Expenses | $78.80M |
| Nonoperating Income/Loss | $6.95M |
| Operating Expenses | $85.75M |
| Research and Development | $56.04M |
| Other Operating Expenses | $29.71M |
| Operating Income/Loss | -$41.98M |
| Income/Loss From Continuing Operations After Tax | -$35.04M |
| Income/Loss From Continuing Operations Before Tax | -$35.04M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$35.04M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$35.04M |
| Net Income/Loss Available To Common Stockholders, Basic | -$35.04M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.19 |
| Diluted Earnings Per Share | -$4.19 |
| Basic Average Shares | 8,359,109 |
| Assets | $154.69M |
| Current Assets | $145.03M |
| Noncurrent Assets | $9.66M |
| Fixed Assets | $3.89M |
| Other Non-current Assets | $5.77M |
| Liabilities | $119.41M |
| Current Liabilities | $56.27M |
| Accounts Payable | $3.17M |
| Other Current Liabilities | $53.11M |
| Noncurrent Liabilities | $63.14M |
| Equity | $35.27M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $35.27M |
| Liabilities And Equity | $154.69M |
| Net Cash Flow From Operating Activities | -$4.99M |
| Net Cash Flow From Operating Activities, Continuing | -$4.99M |
| Net Cash Flow From Investing Activities | -$518.00K |
| Net Cash Flow From Investing Activities, Continuing | -$518.00K |
| Net Cash Flow From Financing Activities | $87.78M |
| Net Cash Flow From Financing Activities, Continuing | $87.78M |
| Net Cash Flow | $82.27M |
| Net Cash Flow, Continuing | $82.27M |
| Comprehensive Income/Loss | -$35.04M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$35.04M |
| Other Comprehensive Income/Loss | $0.00 |